Each prolonged&#45

An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Multiple Oral Dose, Crossover Bioequivalence Study of Tramadol Retard GPO (100 mg) (Tramadol Hydrochloride 100 mg Extended- Release Tablets) of The Government Pharmaceutical Organization, Thailand with Tramal Retard 100 mg (Tramadol Hydrochloride 100 mg Prolonged Release Tablets) of Grunenthal GmbH, AACHEN, Federal Republic of Germany in Normal, Healthy, Adults Human Subjects under Fasting Conditions

An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of Pantoprazole GPO (40 mg) (Pantoprazole 40 mg Delayed-Release Tablets) of The Government Pharmaceutical Organization, Thailand with CONTROLOC (Pantoprazole 40 mg Gastro-Resistant Tablets) of Takeda GmbH, Germany, in Normal, Healthy, Adults Human Subjects under Fasting Conditions

An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of DOLUGRASE (50 mg) (Dolutegravir 50 mg Tablets) of The Government Pharmaceutical Organization, Thailand with TIVICAY (Dolutegravir 50 mg Tablets) of Glaxo Operations UK Ltd, United Kingdom, in Normal, Healthy, Adults Human Subjects under Fasting Conditions

An Open Label, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of Pantoprazole GPO (40 mg) (Pantoprazole 40 mg Delayed-Release Tablets) of The Government Pharmaceutical Organization, Thailand with CONTROLOC (Pantoprazole 40 mg Gastro-resistant Tablets) of Takeda GmbH, Germany, in Normal, Healthy, Adults Human Subjects under Fed Conditions